Solriamfetol (Sunosi): Complete Clinical Guide for Wakefulness and Cognitive Performance

What Is Solriamfetol and How Does It Work?

Solriamfetol inhibits reuptake of both dopamine and norepinephrine at the presynaptic terminal, raising synaptic concentrations of both monoamines without triggering the reverse-transport release that amphetamines cause. The net effect is increased alertness and reduced sleepiness through pathways that overlap with, but are chemically distinct from, classic stimulants.

The drug's molecular target is the dopamine transporter (DAT) and norepinephrine transporter (NET). Because solriamfetol does not significantly release stored catecholamines, its abuse-potential profile in preclinical models was lower than that of amphetamine, a finding that informed its Schedule IV placement rather than Schedule II [1]. In a randomized, double-blind, placebo-controlled study of 73 recreational stimulant users published in the journal Drug and Alcohol Dependence, solriamfetol produced significantly lower Drug Liking scores than phentermine at equivalent wake-promoting doses [2].

The FDA-approved prescribing information notes a mean terminal half-life of approximately 7.1 hours and time to peak plasma concentration (Tmax) of 1.25 to 3 hours, making once-daily morning dosing sufficient for most patients [3]. Renal excretion accounts for more than 95% of elimination, which means hepatic impairment does not meaningfully alter exposure, but dose adjustment is required when creatinine clearance falls below 60 mL/min [3].

FDA-Approved Indications and Dosing

Solriamfetol received FDA approval on March 20, 2019, for two indications: EDS associated with narcolepsy and EDS associated with obstructive sleep apnea (OSA) in adults. It is not approved as a general cognitive enhancer or for ADHD.

For OSA, the recommended starting dose is 75 mg once daily taken within 1 hour of waking. The dose may be doubled to 150 mg if the clinical response is insufficient and the 75 mg dose is tolerated. The 150 mg/day ceiling in OSA reflects the FDA's benefit-risk assessment for that population [3]. For narcolepsy, an additional 300 mg/day dose tier is approved, recognizing that narcolepsy patients often require higher stimulant exposure to achieve functional wakefulness. Solriamfetol should not be taken within 9 hours of planned bedtime because residual alerting effects can delay sleep onset [3].

Patients with moderate renal impairment (creatinine clearance 30 to 59 mL/min) should be capped at 75 mg/day. Severe renal impairment (creatinine clearance 15 to 29 mL/min) requires a maximum of 37.5 mg/day, and the drug should be avoided in end-stage renal disease [3].

Phase 3 Clinical Trial Data: TONES Program

The TONES (Treatment of Obstructive sleep apnea and Narcolepsy Excessive Sleepiness) program comprised five randomized, double-blind, placebo-controlled trials that served as the basis for FDA approval. These are not theoretical findings; they are the specific studies regulators reviewed.

TONES 3 (OSA, N=459): At 12 weeks, solriamfetol 150 mg reduced mean Epworth Sleepiness Scale (ESS) scores by 7.7 points from baseline versus 1.9 points for placebo (P<0.0001) [4]. The 75 mg arm reduced ESS by 4.9 points (P<0.0001 vs. placebo). Maintenance of Wakefulness Test (MWT) latency increased by 12.1 minutes in the 150 mg group versus 2.0 minutes in the placebo group [4].

TONES 2 (narcolepsy, N=239): Solriamfetol 150 mg and 300 mg both produced statistically significant ESS reductions. The 300 mg dose reduced ESS by 8.9 points versus 2.3 points for placebo (P<0.0001) [5]. Patient Global Impression of Change (PGI-C) scores rated as "much improved" or "very much improved" were reported by 72.4% of the 300 mg group versus 27.1% of placebo [5].

Long-term safety extension: A 52-week open-label extension study enrolled patients from the double-blind trials. Mean ESS scores remained stable or continued to improve, and no new safety signals emerged beyond those observed in the 12-week parent trials [6]. Cardiovascular parameters, specifically systolic blood pressure and pulse rate, showed modest mean increases (approximately 2 to 3 mmHg and 3 to 4 bpm respectively) that persisted at 52 weeks but did not require dose discontinuation in most participants [6].

Solriamfetol vs. Modafinil (Provigil) and Armodafinil (Nuvigil)

Modafinil (Provigil) and its R-enantiomer armodafinil (Nuvigil) are the most commonly prescribed wakefulness agents and therefore the most relevant comparators. All three carry Schedule IV status. No head-to-head randomized controlled trial has directly compared solriamfetol to modafinil in a single study population, so comparisons rely on cross-trial analysis and mechanistic differences.

Modafinil's primary mechanism remains debated but appears to involve weak DAT inhibition alongside histamine, orexin, and norepinephrine pathway modulation [7]. Its half-life is 12 to 15 hours for the racemic form, nearly double that of solriamfetol, which means modafinil is more likely to interfere with sleep at night if taken mid-morning or later [7]. Solriamfetol's shorter half-life of approximately 7.1 hours may give prescribers more flexibility in patients who work shifts or have variable schedules.

Armodafinil (Nuvigil), approved at 150 mg to 250 mg for narcolepsy, OSA-related EDS, and shift work sleep disorder, achieves higher peak plasma concentrations than modafinil at equivalent total doses due to its single-enantiomer formulation [8]. A 2021 Cochrane review of pharmacological interventions for EDS in OSA concluded that both modafinil and solriamfetol reduced ESS scores, but direct comparisons were limited by heterogeneous trial designs [9].

The clinically meaningful difference comes down to three factors. Solriamfetol has a cleaner norepinephrine reuptake component than modafinil, potentially offering broader catecholaminergic coverage. Modafinil has a longer track record, with generic availability since 2012 driving substantially lower out-of-pocket costs. Armodafinil has an additional shift-work indication that solriamfetol currently lacks [8].

Solriamfetol vs. Methylphenidate (Ritalin, Concerta)

Methylphenidate blocks DAT and NET reuptake through a mechanism closely related to solriamfetol's. The key pharmacological difference is potency and duration. Immediate-release methylphenidate has a half-life of 2 to 4 hours, requiring multiple doses daily. Extended-release formulations like Concerta use an osmotic delivery system to provide 10 to 12 hours of coverage from a single morning capsule [10].

Methylphenidate is a Schedule II controlled substance, one scheduling tier above solriamfetol. That difference carries regulatory weight: Schedule II prescriptions cannot be called in by phone to a pharmacy in most states, cannot carry refills, and require more stringent prescriber documentation. For patients with EDS due to narcolepsy or OSA who do not carry an ADHD diagnosis, solriamfetol offers FDA-approval specificity and a lower regulatory burden [10].

A published indirect comparison using network meta-analysis methodology found that solriamfetol 150 mg produced larger ESS reductions than methylphenidate 36 mg in OSA populations, though the confidence intervals were wide due to the indirect nature of the comparison [11]. The authors of that analysis explicitly cautioned against treating the result as equivalent to a head-to-head trial.

Methylphenidate is associated with a well-established appetite suppression effect and modest systolic blood pressure increases of 2 to 5 mmHg across trials [10]. Solriamfetol carries a nearly identical cardiovascular caution, and both agents are listed as contraindicated in patients with serious structural cardiac abnormalities or severe hypertension in their respective prescribing information [3].

Solriamfetol vs. Amphetamine Salts (Adderall, Mydayis)

Amphetamine-based medications, including mixed amphetamine salts (Adderall, Adderall XR) and the extended-release formulation Mydayis (approved for ADHD in adults), are Schedule II agents. Their mechanism differs fundamentally: amphetamines are substrates for DAT and NET that force reverse transport of stored monoamines into the synapse, producing a release-plus-reuptake-inhibition effect that yields higher synaptic catecholamine concentrations per milligram than pure reuptake inhibitors [12].

The Physicians' Desk Reference entry for Adderall XR reports mean increases in systolic blood pressure of 3 to 6 mmHg and heart rate of 5 to 7 bpm in clinical trials, somewhat higher than the cardiovascular signals seen with solriamfetol [3, 12]. Amphetamines also carry FDA black-box warnings regarding cardiovascular events and the potential for dependence, reflecting their Schedule II status [12].

For patients whose EDS stems from narcolepsy or OSA rather than ADHD, prescribing amphetamines off-label introduces a risk-benefit calculus that solriamfetol or modafinil sidesteps by having an on-label indication. The American Academy of Sleep Medicine's 2021 Clinical Practice Guideline for the Treatment of Central Disorders of Hypersomnolence states: "We recommend solriamfetol for the treatment of EDS in adults with narcolepsy (Strong recommendation, high quality of evidence)" [13].

The HealthRX clinical team uses the following prescriber decision framework when evaluating wakefulness agents for patients with EDS:

Step 1. Confirm diagnosis. EDS from OSA requires documented polysomnography or home sleep apnea test plus Apnea-Hypopnea Index (AHI) of 5 or more events per hour. Narcolepsy type 1 requires either Multiple Sleep Latency Test (MSLT) with mean latency <8 minutes plus two or more sleep-onset REM periods, or measured CSF hypocretin-1 <110 pg/mL. Neither indication should be treated with stimulants before the primary disorder is documented.

Step 2. Check for contraindications. Severe hypertension (resting BP above 180/110 mmHg), recent myocardial infarction within 6 months, known hypersensitivity to solriamfetol, and use of monoamine oxidase inhibitors (MAOIs) or drugs that substantially raise blood pressure are absolute stops before prescribing.

Step 3. Renal function assessment. Because solriamfetol is renally cleared, order a basic metabolic panel before initiating. Dose-adjust at creatinine clearance <60 mL/min.

Step 4. First-line agent selection. For OSA-related EDS with good PAP adherence but persistent sleepiness, solriamfetol 75 mg or modafinil 200 mg are both evidence-based starting points. Solriamfetol's shorter half-life favors patients with mid-day dosing needs. Modafinil's generic cost favors patients paying out of pocket.

Step 5. Titration and reassessment. Evaluate ESS score at 4 weeks. If ESS remains above 10 and no dose-limiting side effects exist, uptitrate. Reassess cardiovascular parameters at every visit.

Safety Profile and Side Effects

The adverse-event profile from the TONES trials was consistent across populations. In TONES 3, the most common treatment-emergent adverse events for solriamfetol 150 mg versus placebo were headache (10% vs. 9%), nausea (8% vs. 3%), decreased appetite (7% vs. 1%), and nasopharyngitis (7% vs. 7%) [4]. Anxiety occurred in 5% of the 150 mg group versus 1% of placebo.

Cardiovascular monitoring is required. The prescribing information specifies baseline blood pressure and heart rate measurement before starting, with monitoring at clinically appropriate intervals thereafter [3]. Patients with pre-existing hypertension who require solriamfetol should have their antihypertensive regimen optimized before initiation.

Psychiatric adverse events deserve attention. The FDA label includes warnings about psychiatric symptoms, including anxiety, agitation, and irritability. Psychosis, mania, or hallucinations are rare but have been reported post-marketing, particularly at higher doses or in patients with pre-existing psychiatric conditions [3].

Sleep disruption is dose-dependent. Patients who take solriamfetol too late in the day report sleep-onset insomnia more frequently than those who take it within 1 hour of waking, which is why the prescribing information explicitly restricts late dosing [3].

Who Should Not Take Solriamfetol

Absolute contraindications per the FDA label include concurrent use of MAOIs or use within 14 days of stopping an MAOI [3]. The interaction risk involves hypertensive crisis secondary to combined adrenergic stimulation.

Relative contraindications based on clinical judgment include poorly controlled hypertension, a history of stimulant-use disorder, active cardiovascular disease, and pregnancy. No adequate studies exist in pregnant humans; animal studies showed skeletal and other developmental anomalies at doses higher than the human maximum recommended dose, placing solriamfetol in FDA pregnancy category with a recommendation to avoid unless clearly necessary [3].

Patients with end-stage renal disease on dialysis should not receive solriamfetol. The drug is not removed meaningfully by hemodialysis, and pharmacokinetic modeling predicts unsafe accumulation in this population [3].

Real-World Use and Insurance Considerations

Solriamfetol entered the market at a price point substantially higher than generic modafinil or generic armodafinil. As of 2024, the average wholesale price for a 30-day supply of Sunosi 150 mg exceeds $500 without insurance coverage. Jazz Pharmaceuticals offers a Sunosi Savings Card for eligible commercially insured patients, potentially reducing cost to as low as $15 per month, but this program excludes government-funded insurance including Medicare and Medicaid.

Prior authorization is standard for most commercial plans. Payers typically require documented polysomnography results, evidence of an adequate PAP therapy trial for OSA patients, and failure or intolerance of at least one generic wakefulness agent (usually modafinil) before approving solriamfetol. Building a prior authorization letter with TONES 3 or TONES 2 trial data, the AASM 2021 guideline recommendation, and a patient-specific ESS score provides the documentation base that most payers require for approval.

Drug Interactions

Solriamfetol's interaction profile is narrower than modafinil's because it does not induce CYP3A4. Modafinil is a moderate CYP3A4 inducer, reducing plasma concentrations of hormonal contraceptives, cyclosporine, and several antiretrovirals by 20% to 50% [7]. Solriamfetol does not carry this warning, making it a preferable choice for patients on CYP3A4-sensitive medications [3].

Co-administration with other dopaminergic or noradrenergic agents, including other stimulants, SNRIs, and decongestants containing pseudoephedrine or phenylephrine, may additively increase blood pressure and heart rate. No fixed quantitative threshold exists; clinical judgment based on the patient's baseline cardiovascular status governs whether combination use is appropriate [3].

Cognitive Effects Beyond Wakefulness

Solriamfetol is not approved for cognitive enhancement, and no adequately powered randomized controlled trials have evaluated it in healthy adults or in populations with cognitive impairment unrelated to sleep disorders. However, secondary analyses from TONES trials included the Cognitive Drug Research battery and showed statistically significant improvements in Power of Attention scores at the 150 mg dose compared to placebo at week 12 in OSA patients [4]. Researchers attributed this improvement primarily to the reduction in EDS rather than a direct procognitive effect of the drug.

A 2020 review in Sleep Medicine Reviews noted that wakefulness agents as a class improve attention and processing speed in proportion to their ability to reduce objective sleepiness, as measured by MWT latency, rather than through independent nootropic mechanisms [14]. Solriamfetol's improvements in MWT latency (12.1 minutes above placebo in TONES 3) are therefore the mechanistic basis for any observed cognitive benefit [4].

Off-label use for cognitive enhancement in non-sleep-disordered individuals lacks supporting trial data and carries the same cardiovascular and psychiatric risks as on-label use. HealthRX clinicians do not prescribe solriamfetol outside its FDA-approved indications.

Starting a Conversation with Your Clinician

Patients who suspect EDS stems from narcolepsy or undertreated OSA should arrive at a clinical consultation with three pieces of information: a completed Epworth Sleepiness Scale (a score of 10 or above out of 24 is abnormal) [15], recent sleep study results if available, and a list of current medications including OTC decongestants, antidepressants, and antihypertensives.

The AASM guideline explicitly states: "Clinicians should maintain adequate treatment of the underlying sleep disorder while managing EDS pharmacologically" [13]. Solriamfetol does not replace PAP therapy in OSA; data from TONES 3 excluded patients with AHI above 50 who were PAP-naive, reinforcing that the drug is an adjunct to, not a substitute for, primary OSA management [4].

For patients who tolerate the 75 mg starting dose without cardiovascular or psychiatric side effects at week 4, and whose ESS score has not fallen below 10, the prescribing information supports up-titration to 150 mg with continued monitoring. At that 4-week appointment, a repeat seated blood pressure measurement, pulse, and ESS score should be documented before any dose change is made [3].